Navigation Links
Ritter Pharmaceuticals Hires Dr. Howard Foyt as Executive Vice President, Development & Chief Medical Officer
Date:9/10/2009

LOS ANGELES, Sept. 10 /PRNewswire/ -- Ritter Pharmaceuticals, Inc. (Ritter) has hired Howard Foyt, M.D., Ph.D., FACP as its new Executive VP, Development & Chief Medical Officer. Dr. Foyt brings 13 years of expertise in drug development to Ritter, as the Company prepares to file an IND for its therapy for Lactose Intolerance.

Dr. Foyt will join Ritter's senior management team and oversee the Company's clinical development efforts. Ritter will take advantage of Dr. Foyt's leadership in drug development within big pharma and biotech companies. For the past three years, Dr. Foyt served as VP, Clinical Development and Chief Medical Officer at Metabasis Therapeutics, where he was responsible for five drugs in clinical development over multiple therapeutic areas. Dr. Foyt had previously worked at Pfizer, where he served as Senior Director and Site Head - Diabetes & Obesity, and earlier at Parke-Davis for over ten years participating in the clinical development of multiple drugs mainly in the metabolic disease field. Prior to joining Parke-Davis, Dr. Foyt was on the faculty at the University of Texas Medical Branch, Galveston, TX. He earned his medical degree and Ph.D. in Cell Biology from Baylor College of Medicine. Dr. Foyt completed his residency in internal medicine at Baylor and an endocrinology fellowship at the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.

"We are thrilled to have Dr. Foyt on our team," said Ritter Pharmaceuticals' President and CEO Andrew Ritter. "His breadth of clinical development and drug development experience will bring a great deal of scientific rigor and creativity to our development plans."

About Ritter Pharmaceuticals

Ritter is committed to the discovery, development and commercialization of innovative therapies for gastrointestinal diseases. The Company's scientific platform of gastrointestinal physiology, metabolism and gut adaptation brings creativity to providing unique therapeutic approaches to a variety of GI diseases, including lactose intolerance, irritable bowel syndrome, Crohn's disease, and ulcerative colitis. Ritter's ultimate goal is to improve digestive health and overall quality of life.

Ritter's first compound, RP-G28, has been developed for the treatment of lactose intolerance. RP-G28 will effectively stand out as the first FDA-approved drug for the treatment of lactose intolerance.

www.ritterpharma.com


'/>"/>
SOURCE Ritter Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Reportlinker Adds US and European Radiopharmaceuticals Market Report
2. Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever
3. Isis Pharmaceuticals to Present at Morgan Stanleys Global Healthcare Unplugged Conference
4. Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer
5. Jazz Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Amira Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference
8. Steven Holtzman Joins Satori Pharmaceuticals Board of Directors
9. Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer
10. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2010
11. Isis Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... ... Haute Living, is proud to recognize Dr. Barry M. Weintraub as a prominent ... “the most beautiful women in the world, and the most handsome men, look ...
(Date:6/24/2016)... ... 24, 2016 , ... National recruitment firm Slone Partners is pleased ... and genomics experience, as Vice President of North American Capital Sales at HTG ... leading the sales team in the commercialization of the HTG EdgeSeq system and associated ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
Breaking Medicine Technology: